Get the latest on MindMed’s Q3 2025 earnings: clinical trial milestones, financial strength, and pivotal Phase III data readouts expected in 2026.
Amylyx now expects to complete recruitment for the LUCIDITY Phase III trial in Q1 2026 with top line data expected in Q3 2026, shifting both timelines by approximately one quarter from previous ...
Health care occupations, as well as data science and tech related jobs, are expected to see among the fastest growth in ...
The giant domestic policy bill that congressional Republicans passed this summer is about to make Equifax’s services even ...
TipRanks on MSN
FDA Opens the Door for AI in Clinics, Priming Market for $2.7T Digital Health Wave by 2035
Vancouver, Canada, November 4th, 2025, FinanceWire USA News Group News Commentary – Healthcare’s embrace of AI is moving from ...
New work requirements are expected to leave millions of poor Americans uninsured. For Equifax, which charges states steep ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
CVS Health rode double-digit sales growth from drugstores and its pharmacy benefits management business to a ...
StockStory.org on MSN
Data Analytics Stocks Q2 Recap: Benchmarking Health Catalyst (NASDAQ:HCAT)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the data ...
While research has long held the far right to be the most persistent domestic terror threat, a controversial new report ...
WILMINGTON, Del.--(BUSINESS WIRE)--$INCY #ESMO2025--Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising ...
CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback